For: | Ren P, Yu ZT, Xiu L, Wang M, Liu HM. Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2013; 19(15): 2412-2418 [PMID: 23613637 DOI: 10.3748/wjg.v19.i15.2412] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v19/i15/2412.htm |
Number | Citing Articles |
1 |
Anton Neschadim, Alastair J.S. Summerlee, Joshua D. Silvertown. Targeting the relaxin hormonal pathway in prostate cancer. International Journal of Cancer 2015; 137(10): 2287 doi: 10.1002/ijc.29079
|
2 |
Y Xu, Q Yu, Y Liu. Serum relaxin-2 as a novel biomarker for prostate cancer. British Journal of Biomedical Science 2018; 75(3): 145 doi: 10.1080/09674845.2018.1424499
|
3 |
Yuan Yuan Li, Ling Bin Du, Xiao Qian Hu, Sanjay Jaiswal, Shu Yan Gu, Yu Xuan Gu, Heng Jin Dong. A suggested framework for conducting esophageal cancer screening in China. Journal of Digestive Diseases 2018; 19(12): 722 doi: 10.1111/1751-2980.12675
|
4 |
A Wang, Y Tan, X Geng, X Chen, S Wang. Lymphovascular invasion as a poor prognostic indicator in thoracic esophageal carcinoma: a systematic review and meta-analysis. Diseases of the Esophagus 2019; 32(2) doi: 10.1093/dote/doy083
|
5 |
Louis Boafo Kwantwi. The dual and multifaceted role of relaxin-2 in cancer. Clinical and Translational Oncology 2023; 25(10): 2763 doi: 10.1007/s12094-023-03146-0
|
6 |
Deepika Karki, Prashant Pant, Asim Shrestha, Suchit Thapa Chhetri, Isabel Kadel, Gagan Prakash Karna. Esophageal squamous carcinoma in a 25‐year‐old female, changing trend in epidemiology: A case report. Clinical Case Reports 2023; 11(11) doi: 10.1002/ccr3.8134
|
7 |
Adam N. Bennett, Rui Xuan Huang, Qian He, Nikki P. Lee, Wing-Kin Sung, Kei Hang Katie Chan. Drug repositioning for esophageal squamous cell carcinoma. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.991842
|
8 |
Camilla Sköld, Sara Corvigno, Hanna Dahlstrand, Gunilla Enblad, Artur Mezheyeuski, Inger Sundström-Poromaa, Karin Stålberg, Anna Tolf, Ingrid Glimelius, Anthoula Koliadi. Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer. Cancer Causes & Control 2024; 35(8): 1101 doi: 10.1007/s10552-024-01876-2
|
9 |
Shanghui Guan, Cong Wang, Xuan Chen, Bowen Liu, Bingxu Tan, Fang Liu, Ding Wang, Lihui Han, Lu Wang, Xiaochen Huang, Jiangfeng Wang, Bin Yao, Jialei Shi, Pengxiang Chen, Effat Un Nesa, Qingxu Song, Yufeng Cheng. MiR-613: a novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma. Tumor Biology 2016; 37(4): 4383 doi: 10.1007/s13277-015-4271-8
|
10 |
Yuichiro Kikkawa, Satoshi Matsuo, Ryota Kurogi, Akira Nakamizo, Masahiro Mizoguchi, Tomio Sasaki. Upregulation of Relaxin after Experimental Subarachnoid Hemorrhage in Rabbits. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/836397
|
11 |
Kamila Domińska, Kinga Anna Urbanek, Karolina Kowalska, Dominika Ewa Habrowska-Górczyńska, Marta Justyna Kozieł, Tomasz Ochędalski, Agnieszka Wanda Piastowska-Ciesielska. The consequences of manipulating relaxin family peptide receptor 1 (RXFP1) level in ovarian cancer cells. Reproductive Biology 2024; 24(2): 100864 doi: 10.1016/j.repbio.2024.100864
|
12 |
Michelle L. Halls, Ross A.D. Bathgate, Steve W. Sutton, Thomas B. Dschietzig, Roger J. Summers. International Union of Basic and Clinical Pharmacology. XCV. Recent Advances in the Understanding of the Pharmacology and Biological Roles of Relaxin Family Peptide Receptors 1–4, the Receptors for Relaxin Family Peptides. Pharmacological Reviews 2015; 67(2): 389 doi: 10.1124/pr.114.009472
|
13 |
Roger J. Summers, Michelle L. Halls, Ross A. D. Bathgate. Encyclopedia of Signaling Molecules. 2018; : 4583 doi: 10.1007/978-3-319-67199-4_362
|
14 |
Alana Aragón-Herrera, Sandra Feijóo-Bandín, Laura Anido-Varela, Sandra Moraña-Fernández, Esther Roselló-Lletí, Manuel Portolés, Estefanía Tarazón, Oreste Gualillo, José González-Juanatey, Francisca Lago. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases. Journal of Personalized Medicine 2022; 12(7): 1021 doi: 10.3390/jpm12071021
|
15 |
Jungchan Jung, Hyunho Han. The diverse influences of relaxin-like peptide family on tumor progression: Potential opportunities and emerging challenges. Heliyon 2024; 10(2): e24463 doi: 10.1016/j.heliyon.2024.e24463
|
16 |
Gino Marioni, Roberto Di Carlo, Giancarlo Ottaviano, Rocco Cappellesso, Alberto Bedogni, Rosario Marchese-Ragona, Paola Stritoni, Marco Rossi, Elisabetta Zanoletti, Niccolò Favaretto, Elisa Valentini, Federico Apolloni, Luciano Giacomelli, Alessandro Martini, Stella Blandamura. Relaxin-2 Expression in Oral Squamous Cell Carcinoma. The International Journal of Biological Markers 2016; 31(3): 324 doi: 10.5301/jbm.5000219
|
17 |
Xiaojing Guo, Yujie Liu, Xia Huang, Yun Wang, Jin Qu, Yingpin Lv. Serum relaxin as a diagnostic and prognostic marker in patients with epithelial ovarian cancer. Cancer Biomarkers 2017; 21(1): 81 doi: 10.3233/CBM-170278
|
18 |
Roger J. Summers, Michelle L. Halls, Ross A. D. Bathgate. Encyclopedia of Signaling Molecules. 2016; : 1 doi: 10.1007/978-1-4614-6438-9_362-1
|
19 |
Rafael Clara Martins, Mariana Pintalhão, Adelino Leite-Moreira, Paulo Castro-Chaves. Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice. Current Molecular Medicine 2020; 20(3): 167 doi: 10.2174/1566524019666191023121607
|
20 |
Misaki Fue, Yasuhiro Miki, Kiyoshi Takagi, Chiaki Hashimoto, Nobuo Yaegashi, Takashi Suzuki, Kiyoshi Ito. Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the β-Catenin Pathway in Endometrial Cancer. International Journal of Molecular Sciences 2018; 19(8): 2438 doi: 10.3390/ijms19082438
|